Kayleigh R Marx

8PUBLICATIONS
44CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)HaematologyPhycology (incl. marine grasses)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 20, 2026
Evaluation of hypomethylating agents with or without venetoclax in patients with accelerated phase and blast phase myeloproliferative neoplasms: a HERO consortium study.

|Apr 07, 2025
Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial.

Hannah Goulart, Hagop Kantarjian, Gautam Borthakur

|Mar 26, 2025
Multicenter Retrospective Evaluation of Treatment for High-Risk Acute Promyelocytic Leukemia: Real-World Outcomes From the HERO Consortium.

Lydia L Benitez, Kayleigh R Marx, Caitlin R Rausch

|Aug 28, 2023
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.

Tapan M Kadia, Farhad Ravandi, Matteo Molica

|Mar 07, 2023
Association between bariatric surgery and outcomes in chronic myeloid leukemia.

Fadi G Haddad, Hagop M Kantarjian, Aram Bidikian

|Oct 12, 2022
Incidence of adverse effects in patients receiving ponatinib with concomitant azole antifungals.

Kayleigh R Marx, Caitlin R Rausch, Alexandra R Lovell

Pageof 2

Frequent Collaborators

5 joint publications

Tapan M Kadia

5 joint publications

Caitlin Rausch

5 joint publications

Guillermo Garcia-Manero

4 joint publications

Courtney D DiNardo